Onconetix, Inc. (ONCO) vs Nuvilex Inc. (PMCB)

Onconetix, Inc. and Nuvilex Inc. are both Biotechnology companies. Onconetix, Inc. and Nuvilex Inc. are of similar size ($4.9M and $4.6M). Nuvilex Inc. has negative trailing earnings, so its P/E is not meaningful; Onconetix, Inc. trades at 0.0×. Onconetix, Inc. grew revenue faster over the last twelve months: −51.3% against −71.1%. Nuvilex Inc. has the higher net margin (0.00% vs −1,578.6%) and the higher return on invested capital (0.00% vs −135.4%). Across the 15 metrics below, Nuvilex Inc. leads on 9 and Onconetix, Inc. on 6.

Valuation

Metric ONCO PMCB Biotechnology median
P/E 0.00 n/m 7.88
P/S 3.58 n/m 11.47
P/B 0.17 0.17 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.22 3.67 0.74
EV/Sales (5.44) n/m 10.73
Earnings yield 24,089.32% (509.84%) (28.84%)
Free cash flow yield (447.45%) (224.12%) (23.03%)

Profitability

Metric ONCO PMCB Biotechnology median
Gross margin 80.38% 95.64% 65.16%
Operating margin (2,524.73%) 0.00% 0.00%
Net margin (1,578.60%) 0.00% 0.00%
Free cash flow margin (1,595.90%) 0.00% 0.00%
Return on equity (105.23%) (58.04%) (57.72%)
Return on assets (57.37%) (50.43%) (49.22%)
Return on invested capital (135.42%) 0.00% 0.00%

Growth

Metric ONCO PMCB Biotechnology median
Revenue growth (TTM) (51.33%) (71.06%) 5.64%
EPS growth (last fiscal year) 99.09% (186.83%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ONCO PMCB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.21 40.29 4.73
Net debt to EBITDA 0.29 5.41 0.96

Dividend

Metric ONCO PMCB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ONCO PMCB Biotechnology median
Market cap 4.61m 4.90m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack